Nachrichten zur Exelixis Inc. Aktie

Why Exelixis Stock Trounced the Market on Thursday

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that its making a…

Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter…

2 Stocks to Buy With Less Than $40

Some think investing in stocks requires substantial start-up capital, but thats false. Even with a modest sum, like $40, investors…

Exelixis ist mit Cabometyx-Erfolg ein Top-Breakout-Kandidat unter den Biotech-Stocks!

Mehrere Biotechfirmen überraschen gerade mit ihren vorläufigen Quartalsergebnissen. Hier zählt nun auch Exelixis (EXEL) nach dem bereits erfolgreichen Big-Picture-Breakout zu…

Brookline Capital sets $40 target on Exelixis stock with Buy rating By Investing.com

Brookline Capital sets $40 target on Exelixis stock with Buy rating…

2 Biotech Stocks to Buy Hand Over Fist in December

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark,…

Exelixis nutzt Tyrosinkinase-Inhibitoren zur Krebsbehandlung - Zanzalintinib liefert eine zusätzliche 5 Mrd. USD-Umsatzchance bis 2033!

Das Biotechunternehmen Exelixis (EXEL) hat sich auf Tyrosinkinase-Inhibitoren zur Krebsbehandlung spezialisiert. Diese können Enzyme blockieren und damit das Tumorwachstum sowie…

End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL)

InterDigital, Futu Holdings and Exelixis are all stocks with reasonable valuations and bullish catalysts…

Nach einer Prognoseanhebung und einem Up-Gap könnte die Aktie von Exelixis nun das Allzeithoch in Angriff nehmen!

Über Exelixis habe ich das letzte Mal nach den starken Q2-Zahlen im Juli berichtet. Die Aktie konnte in den letzten…

Exelixis, Inc. 2024 Q3 - Results - Earnings Call Presentation

…

Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript

…

Zacks.com featured highlights Genpact, MPLX, Exelixis, Paramount Global and H&R Block

Genpact, MPLX, Exelixis, Paramount Global and H&R Block have been highlighted in this Screen of The Week article.…

5 Top-Ranked Value Stocks With Discounted PEG Ratio to Buy

Five PEG-based stocks that fulfill our screening criteria are Genpact, MPLX, Exelixis, Paramount Global and H&R Block.…

Exelixis, Inc. (EXEL) Q2 2024 Earnings Call Transcript

…

Ipsen expands collaboration agreement with Exelixis

…

Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript

…

Exelixis, Inc.s (NASDAQ:EXEL) Financials Are Too Obscure To Link With Current Share Price Momentum: Whats In Store For the Stock?

Exelixis (NASDAQ:EXEL) has had a great run on the share market with its stock up by a significant 5.1% over…

Exelixis director Garber Alan M sells shares worth over $460k By Investing.com

Exelixis director Garber Alan M sells shares worth over $460k…

Exelixis expects 2023 revenue of ~$1.83B

…

Exelixis, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Exelixis reports positive results for Cabometyx in treating neuroendocrine tumors

…

Exelixis started at buy at Wainwright on targeted oncology pipeline

…

Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive

Exelixis (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine…

Exelixis reports positive results for Cabometyx in pancreatic cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Exelixis appoints Amy Peterson as Chief Medical Officer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Exelixis appoints Amy Peteson as Chief Medical Officer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K EXELIXIS, INC. For: Aug 23

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Exelixis stock price raised to $29 vs. $25 at Oppenheimer

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Exelixis lead product hits main goal in Phase 3 prostate cancer trial

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Exelixis, Ipsen Say Prostate Cancer Phase 3 Trial Met One of Two Main Goals

Exelixis, Ipsen Say Prostate Cancer Phase 3 Trial Met One of Two Main Goals...…

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared…

dpa-AFX ProFeed